Helligsoe Anne Sophie Lind, Henriksen Louise Tram, Kenborg Line, Dehlendorff Christian, Winther Jeanette Falck, Hasle Henrik
Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Pediatr Blood Cancer. 2021 Sep;68(9):e29098. doi: 10.1002/pbc.29098. Epub 2021 May 22.
To ensure external validation of a study population in clinical late-effect studies of childhood cancer, the participation rate must be high. This study investigated demographic data in Nordic late-effect studies and potential factors impacting participation rates such as cancer type, time since diagnosis, and duration of clinical examinations. We found 80 published studies originating from 16 cohorts, with median follow-up of 6.0 years (range 3-14). The overall participation rates ranged from 27% to 100%. The highest participation rates were seen in studies of survivors with solid tumors (92%) and the lowest in hematologic malignancies (67%) and central nervous system tumors (73%). The clinical examination in 10 studies (62.5%) lasted for more than 3 hours. Neither duration of the clinical examination nor time since diagnosis seemed to affect the participation rate. We encourage future studies to describe the recruitment process more thoroughly to improve understanding of the factors influencing participation rates.
为确保在儿童癌症临床迟发效应研究中对研究人群进行外部验证，参与率必须很高。本研究调查了北欧迟发效应研究中的人口统计学数据以及影响参与率的潜在因素，如癌症类型、确诊后的时间以及临床检查的持续时间。我们发现了80项已发表的研究，这些研究来自16个队列，中位随访时间为6.0年（范围3 - 14年）。总体参与率在27%至100%之间。实体瘤幸存者研究中的参与率最高（92%），血液系统恶性肿瘤（67%）和中枢神经系统肿瘤（73%）的参与率最低。10项研究（62.5%）中的临床检查持续时间超过3小时。临床检查的持续时间和确诊后的时间似乎都不影响参与率。我们鼓励未来的研究更全面地描述招募过程，以增进对影响参与率因素的理解。
